ELMD vs INGN vs LNTH vs LUNG vs MDT

For growth investors, Electromed, Inc.

(ELMD) is the stronger pick with 17. 0% revenue growth year-over-year, versus 0. 5% for Lantheus Holdings, Inc. (LNTH). Medtronic plc (MDT) offers the better valuation at 21. 1x trailing P/E (13. 8x forward), making it the more compelling value choice. Analysts rate Electromed, Inc. (ELMD) a "Buy" — based on 4 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Medtronic plc (MDT) is the cheapest at 21.

1x versus Electromed, Inc. at 31. 3x. On forward P/E, Medtronic plc is actually cheaper at 13. 8x. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: Electromed, Inc. wins at 1. 91x versus Medtronic plc's 35. 17x — a reasonable growth-adjusted valuation.

Over the past 5 years, Lantheus Holdings, Inc.

(LNTH) delivered a total return of +338. 1%, compared to -96. 8% for Pulmonx Corporation (LUNG). Over 10 years, the gap is even starker: LNTH returned +42. 9% versus LUNG's -96. 8%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Medtronic plc (MDT) is the lower-risk stock at 0.

42β versus Pulmonx Corporation's 2. 31β — meaning LUNG is approximately 444% more volatile than MDT relative to the S&P 500. On balance sheet safety, Lantheus Holdings, Inc. (LNTH) carries a lower debt/equity ratio of 0% versus 104% for Pulmonx Corporation — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Electromed, Inc.

(ELMD) is pulling ahead at 17. 0% versus 0. 5% for Lantheus Holdings, Inc. (LNTH). On earnings-per-share growth, the picture is similar: Electromed, Inc. grew EPS 48. 3% year-over-year, compared to -21. 8% for Lantheus Holdings, Inc.. Over a 3-year CAGR, LUNG leads at 19. 0% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Lantheus Holdings, Inc.

(LNTH) is the more profitable company, earning 15. 2% net margin versus -59. 7% for Pulmonx Corporation — meaning it keeps 15. 2% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: LNTH leads at 20. 2% versus -59. 3% for LUNG. At the gross margin level — before operating expenses — ELMD leads at 78. 1%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.

By this metric, Electromed, Inc. (ELMD) is the more undervalued stock at a PEG of 1. 91x versus Medtronic plc's 35. 17x. Both stocks trade at elevated growth-adjusted valuations, so expected growth needs to materialise. On forward earnings alone, Medtronic plc (MDT) trades at 13. 8x forward P/E versus 24. 5x for Electromed, Inc. — 10. 7x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for INGN: 270. 4% to $26. 00.

In this comparison, MDT (3.

7% yield) pays a dividend. ELMD, INGN, LNTH, LUNG do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Medtronic plc (MDT) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.

42), 3. 7% yield). Pulmonx Corporation (LUNG) carries a higher beta of 2. 31 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (MDT: +24. 3%, LUNG: -96. 8%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: ELMD is a small-cap high-growth stock; INGN is a small-cap quality compounder stock; LNTH is a small-cap quality compounder stock; LUNG is a small-cap quality compounder stock; MDT is a mid-cap income-oriented stock. MDT pays a dividend while ELMD, INGN, LNTH, LUNG do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.